Recent developments in the treatment of diabetes have gone beyond glycemic control with the approval of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i), both classes with significant cardiovascular and renal protective effects demonstrated in large randomized controlled trials [1, 2]. This evidence concerns the gene GLP1R and diabetes mellitus.